Montanide ISA-51 placebo emulsion

Phase 2

Montanide ISA-51 placebo emulsion is one of 2 therapeutic programs targeting Rhinitis, Allergic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Rhinitis, AllergicRecruiting

Rhinitis, AllergicPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Rhinitis, Allergic

#DrugCompanyPhaseTrials

Montanide ISA-51 placebo emulsion

KKazakh National Agrarian University

Phase 2

1 2

Pollenvax

KKazakh National Agrarian University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Rhinitis, Allergic

NCT07563439

Clinical

Trials by Indication[1]

Rhinitis, Allergic1 trial

A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of PollenVax, Emulsion for Subcutaneous Injection, in Patients With Allergic Rhinitis Induced by Mugwort (Artemisia Vulgaris) Pollen

Recruiting·KKazakh National Agrarian University·Phase 2·NCT07563439·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Montanide ISA-51 placebo emulsion. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Montanide ISA-51 placebo emulsion. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kazakh National Agrarian University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: KKazakh National Agrarian University

Montanide ISA-51 placebo emulsion

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Rhinitis, Allergic1 trial

References

Drug Info

Quick Facts

Related News